LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

Search

Iovance Biotherapeutics Inc

Geschlossen

BrancheGesundheitswesen

2.41 -1.23

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

2.35

Max

2.49

Schlüsselkennzahlen

By Trading Economics

Einkommen

4.5M

-112M

Verkäufe

11M

60M

Gewinnspanne

-186.246

Angestellte

838

EBITDA

8.3M

-102M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+340.91% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

6. Nov. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-30M

915M

Vorheriger Eröffnungskurs

3.64

Vorheriger Schlusskurs

2.41

Nachrichtenstimmung

By Acuity

50%

50%

172 / 372 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Strong Bearish Evidence

Iovance Biotherapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

27. Aug. 2025, 22:51 UTC

Ergebnisse

Wesfarmers Plans Special Payout to Shareholders as Annual Net Profit Rises 14%

27. Aug. 2025, 23:57 UTC

Ergebnisse

Trip.com Group 1H Rev $4.01B

27. Aug. 2025, 23:57 UTC

Ergebnisse

Trip.com Group 1H Adj EPS $1.84

27. Aug. 2025, 23:57 UTC

Ergebnisse

Trip.com Group 1H EPS $1.82

27. Aug. 2025, 23:50 UTC

Market Talk

Nikkei May Decline Amid Caution Over Tariff Impact, Chip Demand -- Market Talk

27. Aug. 2025, 23:39 UTC

Ergebnisse

Correction to Nvidia Earnings Article -- WSJ

27. Aug. 2025, 22:59 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27. Aug. 2025, 22:59 UTC

Market Talk

HP CEO Sees Strong Back-to-School Spending on PCs -- Market Talk

27. Aug. 2025, 22:58 UTC

Ergebnisse

South32 Records Significant Items of $71 Million Tied to Worsley, Mozal

27. Aug. 2025, 22:57 UTC

Ergebnisse

South32 FY Free Cash Flow $192 Million

27. Aug. 2025, 22:56 UTC

Ergebnisse

South32 FY Total Capital Expenditure $1.35 Billion

27. Aug. 2025, 22:56 UTC

Ergebnisse

South32 FY Capital Expenditure $963 Million, Excluding EAIs

27. Aug. 2025, 22:55 UTC

Ergebnisse

South32 Net Cash $123 Million at June 30

27. Aug. 2025, 22:54 UTC

Ergebnisse

South32: Focused on Maintaining Strong Operating Momentum

27. Aug. 2025, 22:53 UTC

Ergebnisse

South32: $144 Million Remains to be Returned to Shareholders Under Program

27. Aug. 2025, 22:53 UTC

Ergebnisse

South32 Extends Capital Management Program for 12 Months

27. Aug. 2025, 22:52 UTC

Ergebnisse

South32 FY Underlying Ebitda $1.93 Billion, Up 7% On-Year

27. Aug. 2025, 22:51 UTC

Ergebnisse

South32 FY Revenue $5.78 Billion, Up 17% On-Year

27. Aug. 2025, 22:51 UTC

Ergebnisse

South32 FY Underlying Earnings $666 Million, Up 75% On-Year

27. Aug. 2025, 22:50 UTC

Ergebnisse

South32 to Pay Final Dividend of 2.6 U.S. Cents/Share

27. Aug. 2025, 22:50 UTC

Ergebnisse

South32 FY Net Profit $213 Million Vs $203 Million Loss Year Earlier

27. Aug. 2025, 22:45 UTC

Ergebnisse

Sandfire Resources Expects FY26 Matsa Capital Expenditure of $148 Million

27. Aug. 2025, 22:44 UTC

Ergebnisse

Sandfire Resources Expects FY26 Motheo Unit Cost of $44/Ton of Ore Processed

27. Aug. 2025, 22:44 UTC

Ergebnisse

Sandfire Resources Expects FY26 Motheo Capital Expenditure of $82 Million

27. Aug. 2025, 22:43 UTC

Ergebnisse

Sandfire Resources Expects FY26 Matsa Unit Cost of $86/Ton of Ore Processed

27. Aug. 2025, 22:43 UTC

Ergebnisse

Nvidia Breaks Sales Record Despite Chinese Trade Hiccups -- 5th Update

27. Aug. 2025, 22:42 UTC

Ergebnisse

Sandfire Resources Expects FY26 Motheo Copper Eq Output to Rise 3% to 61,000 Tons

27. Aug. 2025, 22:42 UTC

Ergebnisse

Sandfire Resources Expects FY26 Matsa Copper Eq Output to Rise 2% to 96,000 Tons

27. Aug. 2025, 22:40 UTC

Ergebnisse

Sandfire Resources Net Debt $123 Million at June 30

27. Aug. 2025, 22:40 UTC

Ergebnisse

Sandfire Resources FY Underlying Ebitda $527.7 Million

Peer-Vergleich

Kursveränderung

Iovance Biotherapeutics Inc Prognose

Kursziel

By TipRanks

340.91% Vorteil

12-Monats-Prognose

Durchschnitt 10.67 USD  340.91%

Hoch 20 USD

Tief 1 USD

Basierend auf 8 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Iovance Biotherapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

8 ratings

5

Buy

2

Halten

1

Sell

Technischer Score

By Trading Central

3.0208 / 3.5Unterstützung & Widerstand

Kurzfristig

Strong Bearish Evidence

Mittelfristig

Bullish Evidence

Langfristig

Weak Bearish Evidence

Stimmung

By Acuity

172 / 372 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Durchschnitt

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Iovance Biotherapeutics Inc

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.